NDATOPICALLOTION
Approved
Jan 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
VALISONE (betamethasone valerate) by Merck & Co. is clinical pharmacology: topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. Approved for psoriasis, atopic eczema, hand eczema. First approved in 1973.
Drug data last refreshed 1w ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VALISONE is a topical corticosteroid lotion containing betamethasone valerate approved in 1973 for inflammatory skin conditions. It treats psoriasis, atopic eczema, and hand eczema by reducing inflammation, itching, and vasodilation through corticosteroid receptor activation. The drug works via percutaneous absorption into the skin, where it is metabolized hepatically and excreted renally.
LOE Approaching
Brand is in late-stage lifecycle with moderate competitive pressure (30/100), signaling smaller teams focused on profitability and transition planning.
Mechanism of Action
CLINICAL PHARMACOLOGY: Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict…
Indications (3)
Worked on VALISONE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.